NEW YORK, March 12 – Abbott Laboratories and Millennium Pharmaceuticals said Monday that they agreed to enter a five-year, $250 million strategic alliance to jointly discover and develop obesity and diabetes drugs.

Under the terms of the agreement, Abbott of Abbott Park, Ill., said it would purchase $250 million worth of Millennium’s common stock. Abbott will acquire $50 million at the closing of the deal and the remaining $200 million over the next two years. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.